Ekso Bionics (NASDAQ:EKSO) CFO Jerome Wong Sells 11,288 Shares

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) CFO Jerome Wong sold 11,288 shares of Ekso Bionics stock in a transaction on Monday, November 10th. The shares were sold at an average price of $4.80, for a total value of $54,182.40. Following the completion of the sale, the chief financial officer directly owned 26,009 shares of the company’s stock, valued at $124,843.20. This trade represents a 30.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Ekso Bionics Trading Down 5.7%

EKSO traded down $0.31 during trading on Thursday, reaching $5.14. 29,091 shares of the company’s stock were exchanged, compared to its average volume of 116,847. The company’s fifty day moving average price is $4.80 and its 200-day moving average price is $16.80. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.57 and a current ratio of 1.66. The firm has a market capitalization of $13.48 million, a PE ratio of -0.90 and a beta of 1.08. Ekso Bionics Holdings, Inc. has a fifty-two week low of $2.73 and a fifty-two week high of $14.97.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.45. Ekso Bionics had a negative return on equity of 90.71% and a negative net margin of 70.74%.The business had revenue of $4.23 million during the quarter, compared to analysts’ expectations of $4.16 million. As a group, equities analysts forecast that Ekso Bionics Holdings, Inc. will post -0.48 EPS for the current year.

Institutional Trading of Ekso Bionics

An institutional investor recently bought a new position in Ekso Bionics stock. Consolidated Portfolio Review Corp bought a new position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 64,883 shares of the company’s stock, valued at approximately $333,000. Consolidated Portfolio Review Corp owned 2.47% of Ekso Bionics as of its most recent filing with the SEC. 6.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $562.50.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.